Here are four things to know:
- There are three FDA approved GLP-1 receptor drugs for obesity: Wegovy, Saxenda and Zepbound. All of these drugs are injectables.
- A total of 63 oral GLP-1 receptor drugs are in development, with four phase 3 products competing for the first approval of an oral version of the drug.
- Novo Nordisk’s Rybelsus, which is FDA approved for Type 2 diabetes, is being tested for obesity treatment. The company also has a phase 3 candidate expected to launch by the end of 2025 that has the highest likelihood of approval in the category, according to the report.
- Eli Lilly’s orforglipron calcium, currently in phase 3 trials, is projected to launch in 2026 as Eli Lilly seeks to expand its GLP-1 receptor portfolio. It could become the first oral GLP-1 receptor drug approved for obesity as well as the first small-molecule GLP-1 receptor approved by the FDA.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
